12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Company News  |  Deals

Panax Pharmaceutical Ltd., Sangen Pharmaceutical Co. deal

PANX and privately held Sangen will merge contingent upon the raising of $10-$15 million in a private direct offering.

PANX's lead product is a tablet for clearing the colon prior to colonoscopy. PANX said the product is poised for Phase II/III trials and anticipates filing an NDA within...

Read the full 222 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >